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ABSTRACT
Background
Pesticide ingestion is a common method of self-harm in the rural developing world. In an
attempt to reduce the high case fatality seen with the herbicide paraquat, a novel formulation
(INTEON) has been developed containing an increased emetic concentration, a purgative, and
an alginate that forms a gel under the acid conditions of the stomach, potentially slowing the
absorption of paraquat and giving the emetic more time to be effective. We compared the
outcome of paraquat self-poisoning with the standard formulation against the new INTEON
formulation following its introduction into Sri Lanka.
Methods and Findings
Clinical data were prospectively collected on 586 patients with paraquat ingestion
presenting to nine large hospitals across Sri Lanka with survival to 3 mo as the primary
outcome. The identity of the formulation ingested after October 2004 was confirmed by assay
of blood or urine samples for a marker compound present in INTEON. The proportion of known
survivors increased from 76/297 with the standard formulation to 103/289 with INTEON
ingestion, and estimated 3-mo survival improved from 27.1% to 36.7% (difference 9.5%; 95%
confidence interval [CI] 2.0%–17.1%; p ¼ 0.002, log rank test). Cox proportional hazards
regression analyses showed an approximately 2-fold reduction in toxicity for INTEON compared
to standard formulation. A higher proportion of patients ingesting INTEON vomited within 15
min (38% with the original formulation to 55% with INTEON, p , 0.001). Median survival time
increased from 2.3 d (95% CI 1.2–3.4 d) with the standard formulation to 6.9 d (95% CI 3.3–10.7
d) with INTEON ingestion (p ¼ 0.002, log rank test); however, in patients who did not survive
there was a comparatively smaller increase in median time to death from 0.9 d (interquartile
range [IQR] 0.5–3.4) to 1.5 d (IQR 0.5–5.5); p ¼ 0.02.
Conclusions
The survey has shown that INTEON technology significantly reduces the mortality of patients
following paraquat ingestion and increases survival time, most likely by reducing absorption.
The Editors’ Summary of this article follows the references.
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Self-poisoning with pesticides is a major public health
problem in many developing countries, accounting for up to
one-third of all suicides worldwide according to recent
estimates [1]. While organophosphorus insecticides are by
far the leading cause of morbidity and mortality in these self-
poisonings, other pesticides are important in speciﬁc regions
and countries [2,3]. Paraquat (1,19-dimethyl-4,49-bipyridinium
dichloride) is a nonselective contact herbicide that has been
widely used in many countries since the 1960s. Following
ingestion of large amounts of concentrated formulation, the
rapid development of multi-organ failure and cardiogenic
shock is almost universally fatal. When smaller amounts are
ingested, paraquat is actively taken up into pulmonary
epithelial cells where redox cycling and free radical gen-
eration trigger a ﬁbrotic process that may lead to death [4–7].
Survival after acute paraquat poisoning is related to the
ingested amount, the circumstances of poisoning, and the
formulation ingested [8]. While intentional ingestion of
paraquat concentrate accounts for most recorded fatalities,
the problem of unintentional ingestion prompted the
introduction of formulation changes (a blue colour, a
stenching agent, and an emetic) to the liquid concentrate in
the late 1970s and early 1980s [9]. This change is believed to
have made a major contribution to the decrease of uninten-
tional paraquat ingestion in many countries [9,10]. However,
mortality following intentional ingestion remains high, and a
beneﬁcial effect of these early formulation changes on the
survival rate has not been demonstrated [11].
GRAMOXONE INTEON is a novel paraquat formulation
speciﬁcally developed to decrease toxicity through a reduc-
tion in the amount of paraquat absorbed from the gastro-
intestinal tract following ingestion [12]. A natural alginate
that immediately gels when entering the low-pH environment
of the stomach has been incorporated into the formulation
and the amount of emetic has been increased. These changes
are designed to improve efﬁcacy of emesis after gelling of the
formulation in the stomach. An osmotic purgative, magne-
sium sulphate, has also been added to the INTEON
formulation to help speed up the passage of remaining
paraquat through the small intestine, the main site of
paraquat uptake, thereby reducing overall absorption.
We carried out an observational study to compare the 3-mo
survival of patients admitted to hospital following paraquat
ingestion before and after the introduction of the new
INTEON formulation in Sri Lanka.
Methods
Patients
The study was conducted in nine large hospitals (in Galle,
Hambantota, Anuradhapura, Polonnaruwa, Colombo, Gam-
paha, Ratnapura, Kandy, and Peradeniya), covering the main
agricultural areas in Sri Lanka, with the exception of the
northern and eastern regions. The protocol (Text S1) was
approved by four separate Ethical Committees (Text S2–S5)
in Sri Lanka with responsibility for surveys/studies conducted
in the nine hospitals. Patients were recruited by study
physicians into the survey if they reported that they had
ingested products containing paraquat or, if the pesticide
ingested was unknown, the patient had clinical signs typical
of paraquat poisoning (mouth lesions and/or blue colouration
around the mouth). Oral informed consent to participate in
the survey was sought from patients or their relatives in their
native language.
Procedures
Data on the exposure, treatment, and outcome of patients
ingesting paraquat were collected prospectively from De-
cember 2003 to January 2006. Following review and approval
of the registration package by the Ofﬁce of the Registrar of
Pesticides, the new INTEON formulation was introduced in
October 2004 and stocks of the existing formulation were
actively withdrawn from distributors and retailers. The
pesticide, bottle, and label were similar to the standard
formulation, the only differences being that the INTEON
formulation was slightly more viscous, and the batch numbers
differed. INTEON also included a tracer compound (500 ppm
diquat) that could be detected in blood and urine following
oral ingestions.
Data were collected by trained research assistants using a
standardised questionnaire. Upon admission, demographic
data (age, sex, and weight) were recorded together with
information relating to previous treatments and transfer
from a primary hospital. Details relating to the ingestion were
taken: time of exposure; circumstances (intentional self-harm,
accidental, homicide, or occupational); time to emesis; and
number and force of vomiting episodes. The patient was asked
to state the ingested volume from a range of quantities (,5m l
to .150 ml) with a variety of measuring schemes (millilitres,
ﬂuid ounces, or various-sized spoon/cup measures).
A plasma and/or urine sample was taken soon after
admission, where possible. Samples were stored frozen and
sent to Syngenta CTL (Alderley Park, Macclesﬁeld, Cheshire,
UK) for determination of paraquat ion concentration and
detection of the tracer compound diquat ion to classify the
case as either standard formulation or INTEON. Analysis was
conducted using HPLC, LC-MS-MS, and LC ﬂuorescence [13].
Details of treatments and clinical observations throughout
the patients’ stay in hospital and clinical outcome were
recorded; if the patient was discharged from hospital, study
doctors visited the patient at home at least 3 mo after the
initial exposure to ascertain survival.
Cases were initially recorded on paper and then trans-
ferred to a Microsoft Access database. For quality control, a
separate database was created from data collected from the
medical notes by an auditor (this was not possible in two of
the hospitals where permission for access to the medical
records archives was refused). The two databases were
compared to assess completeness of case ascertainment and
to highlight differences in recording of details.
To ﬁnd out whether the pattern of patient admissions to,
and referrals from, hospitals not participating in the survey
had changed over time, the study team contacted 147
hospitals and care units towards the end of the survey in
the provinces where the study hospitals were located. Using a
structured questionnaire, information was obtained from
physicians who were in charge of admitting patients, or, in
the case of central dispensaries, from the pharmacists.
Case Definition and Power Calculation
Both standard and INTEON formulation cases were
classiﬁed as ‘conﬁrmed’ on the basis of blood or urine
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(Table 1). The recording of the ﬁrst two consecutive
conﬁrmed INTEON cases at each hospital was taken to
indicate that INTEON use had become common in the area,
and a washout period was deﬁned for each hospital from 1
October 2004 until that time point. Cases after the washout
period without sample conﬁrmation or evidence from the
bottle/label were classiﬁed as ‘possible’ INTEON cases.
The power calculation was based on the Mantel-Haenszel
risk ratio estimate stratiﬁed for three ingestion groups and
indicated that a total of 210 cases would give . 85% power to
detect a 2-fold reduction in potency for a two-sided test with
signiﬁcance level of 5%. It was decided to use the number of
conﬁrmed INTEON cases to close the survey in order to
achieve adequate power for the sensitivity analyses. The
number of conﬁrmed cases fell below 210 after some patients
were identiﬁed with admission records at more than one
hospital after transferring between hospitals and other
patients had to be excluded because they did not meet the
study entrance criteria. However, the total number of
INTEON cases (conﬁrmed, probable, and possible) included
in the analyses exceeded 210.
Statistical Analysis
Means and proportions for baseline variables were com-
pared between the two ingestion groups using Student’s t test
for continuous variables and the v
2 test for categorical
variables. The primary analysis compared survival among
standard formulation cases before 1 October 2004 with
survival among conﬁrmed, probable, and possible INTEON
formulation cases after the washout period. In sensitivity
analyses, survival among all conﬁrmed and probable standard
formulation cases was compared with survival among all
conﬁrmed and probable INTEON formulation cases.
Time to death analyses were performed using both
nonparametric analysis methods (Kaplan–Meier survival
curve estimates and the Mantel–Cox log rank test) and
semiparametric methods (Cox proportional hazards [PH]
regression models). Standard errors for 3-mo survival
estimates were obtained using Greenwood’s method [14]. All
statistical analyses were performed using Stata version 9.
Cox PH regression models were used to estimate unad-
justed and adjusted hazard ratios for the INTEON formula-
tion. Adjusted analyses always included terms for the
following covariates: (a) sex, age, and weight of participant;
(b) treatments received; (c) use of adsorbent; and (d) time
from ingestion to presentation at a medical centre.
Estimated ingestion amount was an important factor
inﬂuencing survival, but information was not available for a
number of cases. Consequently, unadjusted and adjusted
hazard ratios were also derived for the subset of patients who
had ingestion information. Adjustment was performed with
and without estimated ingestion amount in the regression
model. Ingestion amount was included as a categorical
variable (eight levels) but also as a continuous variable using
the logarithms of the midpoint of ingestion categories.
Models were also ﬁtted to examine whether the relationship
with ingestion amount differed between the two groups.
Estimates of relative potency were derived using the slope of
the relationship with the logarithm of ingestion amount and
term for formulation group in the Cox PH model.
Variation in survival characteristics between the nine study
hospitals was investigated using a gamma frailty model
(proportional hazard functions with random scaling factors).
In addition, evidence of nonproportional hazard functions
was assessed by visual methods and by testing the signiﬁcance
of the interaction with the logarithm of survival time.
Stratiﬁcation was used to account for nonproportionality of
the hazard functions.
Results
Information was collected by the nine study hospitals on
774 patients over the study period. The numbers of
participants eligible for the primary analysis and sensitivity
analyses broken down by formulation are given in Table 2.
The primary study population included 297 conﬁrmed cases
of standard formulation ingestion admitted before 1 October
2004 and 289 conﬁrmed, probable and possible cases of
INTEON ingestion. For sensitivity analyses all conﬁrmed or
probable cases were used (382 standard formulation and 206
INTEON cases).
The two primary study populations were similar for
demographic and ingestion variables at baseline (Table 3).
Most patients had ingested paraquat deliberately (93.7% of all
cases). Information on ingestion volume was not available for
a higher percentage of standard formulation than INTEON
Table 1. Categorisation of Cases into Standard Formulation and INTEON Formulation Groups
Formulation Category Before
1 October 04
After
1 October 04
Confirmation of Product Identity Recorded after
Washout Period
b
Paraquat
Present
Diquat
Present
Bottle or Label
Confirmation
Standard formulation Confirmed þ n/a n/a n/a n/a
Confirmed  þþ  
a n/a n/a
Probable  þn/a n/a þ n/a
INTEON formulation Confirmed  þþ þ n/a n/a
Probable  þn/a n/a þ n/a
Possible  þn/a n/a  þ
aProvided there was sufficient paraquat present to ensure the detectability of diquat.
bDefined individually for each hospital as the time from 1 October 2004 until the recording of the first two consecutive confirmed INTEON cases.
þ,y e s ; , no; n/a, not applicable or not available.
doi:10.1371/journal.pmed.0050049.t001
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subgroups was different between the two formulations.
The clinical characteristics of the two groups were
generally similar (Table 4), but a signiﬁcantly higher
proportion of INTEON patients vomited within 15 min of
ingestion. Just over half of all patients were treated at a
primary hospital before being referred to a study hospital
and this proportion was higher for patients who had ingested
INTEON formulation (57.8% versus 45.5%). Lavage, intra-
venous ﬂuids, and prednisolone were the only treatments for
which there was a signiﬁcant difference between the two
groups. Fewer INTEON patients received these treatments
than patients who had ingested the standard formulation
paraquat.
Follow-up of patients was generally good (Table 5), but it
was not possible to ﬁnd out whether ten patients (4.4% of
those followed up) were still alive at 3 mo. Four INTEON
patients were followed up slightly early (a minimum of 11 wk
after ingestion) and are described as alive in Table 5. The
proportion of known survivors increased from 76 of 297
patients with the standard formulation to 103 of 289 patients
with INTEON ingestion, and there was an increase in
estimated 3-mo survival (Kaplan–Meier estimates) among
the INTEON patients from 27.1% to 36.7% (difference 9.6%;
95% CI 2.0%–17.1%). Kaplan–Meier survival analysis (Figure
1) and log rank test indicated a signiﬁcant difference between
the two survival curves (p ¼ 0.002). Median survival time
increased from 2.3 d (95% CI 1.2–3.4 d) with the standard
formulation to 6.9 d (95% CI 3.3–10.7 d) with INTEON
ingestion (p ¼ 0.002, log rank test).
The overall improvement in survival among patients who
had ingested the INTEON formulation was seen in every
ingestion group except the ,5 ml group, in which survival
was already high. Figure 2 shows summary Kaplan–Meier
survival curves for patients categorised into four ingestion
groups (,10 ml, 10–30 ml, 30–100 ml, and  100 ml) for each
formulation. In addition, survival curves are shown for
patients for whom ingestion information was not available.
Survival following ingestion of INTEON was signiﬁcantly
better than the standard formulation (hazard ratio [HR] 0.73,
95% CI 0.60–0.89; p ¼ 0.002) in an unadjusted analysis (Table
6). There was evidence of nonproportionality of the hazard
functions of different hospitals, and stratiﬁcation was used to
account for this. However, HR changed only slightly when
Table 2. Survey Participants
Category Patients n
Total cases (1 December
2003 to 26 January 2006)
—7 7 4
a
Exclusions — 97
Non-oral exposure 30
Consent refused 8
Incomplete record 5
Unintentional poisoning with illicit alcohol
b 36
Washout period cases without sample
confirmation or bottle/label information
18
Standard
formulation cases
—3 8 2
Before 1 October 2004
c 297
Washout period—confirmed
with plasma/urine analysis
38
Washout period—probable
(bottle or label information)
—
Post washout period—confirmed
with plasma/urine analysis
47
Post washout period—probable
(bottle or label information)
—
INTEON cases — 295
Washout period—confirmed
with plasma/urine analysis
6
Washout period—probable
(bottle or label information)
—
Post washout period—confirmed
with plasma/urine analysis
c
195
Post washout period—probable
(bottle or label information)
c
5
Post washout period—possible
c 89
aIncludes five patients with records at two centres.
bIn a single incident, 36 patients ingested kassipu (illegally brewed alcoholic drink) to
which a small amount of paraquat had been added. It was not possible to establish which
formulation had been used or how much paraquat had been ingested.
3Dataset used in the primary analysis.
doi:10.1371/journal.pmed.0050049.t002
Table 3. Demographic and Ingestion Details of Patients in the Formulation Groups
Category Group Standard Formulation Cases
before 1 October 04 (n ¼ 297)
Confirmed, Probable, or
Possible INTEON Cases
(after Washout Period) (n ¼ 289)
Demographic details Male (%) 230 (77.4) 233 (80.6)
Age, y (mean 6 SD) 31.0 6 13.7 29.3 6 12.4
Weight, kg (mean 6 SD) 55.0 6 8.1 56.4 6 9.0
Ingestion details Deliberate ingestion (%) 282 (94.9) 267 (92.4)
Ingestion amount known (%) 221 (74.4) 248 (85.8)***
,5 ml 37 (16.7) 32 (12.9)
5t o,10 ml 18 ( 8.1) 25 (10.1)
10 to ,15 ml 24 (10.9) 43 (17.3)
15 to ,30 ml 31 (14.0) 45 (18.1)
30 to ,50 ml 22 (10.0) 30 (12.1)
50 to ,100 ml 26 (11.8) 31 (12.5)
100 to 150 ml 25 (11.3) 14 ( 5.6)
.150 ml 38 (17.2) 28 (11.3)
*** p , 0.001. SD, standard deviation.
doi:10.1371/journal.pmed.0050049.t003
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covariates other than estimated ingestion amount were
included in the model. Table 6 also shows that HRs were
smaller when these analyses were restricted to the group of
patients with ingestion information, but the fully adjusted
analysis (including ingestion amount) for this latter group of
patients gave an HR of 0.67 (95% CI 0.52–0.87), which is
similar to that seen in the unadjusted analysis for all
participants.
Replacing the eight-level categorical variable for ingestion
amount with the logarithm of the midpoint of ingestion in
each category made little difference to the ﬁt of the model
(change in v
2 ¼ 3.62, 6 df) and there was no evidence of a
different relationship with ingestion amount for the standard
and INTEON formulations. The HR for a doubling of
ingestion amount was 1.57 (95% CI 1.46–1.69). The strong
relationship with the logarithm of ingestion amount enables
an estimate to be made of the potency (toxicity) of the
INTEON formulation relative to the standard formulation.
Based on the subset of patients with ingestion information,
the potency of INTEON was estimated to be 0.54 of the
standard formulation.
Sensitivity analyses including all conﬁrmed and probable
cases gave results that were very similar to those obtained in
the primary analysis. There was an increase in estimated 3-mo
survival among the INTEON patients from 27.4% to 37.9%
(difference 10.5%; 95% CI 2.5%–18.6%) and an HR of 0.64
(95% CI 0.50–0.82) with a potency estimate for INTEON of
0.47 of the standard formulation.
Among patients who died there was an increase in median
time to death from 0.9 d (interquartile range [IQR] 0.5–3.4)
for the standard formulation to 1.5 d for INTEON (IQR 0.5–
5.5); p ¼ 0.02. This effect was more pronounced in the
sensitivity analysis, restricted to conﬁrmed and probable
cases, where the median time to death was 1.1 d (IQR 0.5–3.9)
for the standard formulation but 2.5 d for INTEON (IQR 0.8–
9.0); p ¼ 0.001.
Monthly admissions of patients with paraquat poisoning to
study hospitals showed some seasonal variability, related to
the use pattern of paraquat in Sri Lanka (Figure 3). However,
they also suggest an overall decrease of the number of cases
over time. In the separate admission and referral survey of
147 contacted hospitals and care units, 83 (56%) reported
having received a total of 541 patients with paraquat
Table 4. Clinical Details of Patients in the Formulation Groups
Detail Standard Formulation
Cases before 1 October 04
(n ¼ 297), n (%)
Confirmed, Probable, or Possible
INTEON Cases (after Washout Period)
(n ¼ 289), n (%)
Treated at primary hospital 135 (45.5) 167 (57.8)**
Vomited within 15 min 113 (38.0) 158 (54.7)***
Treated within 4 h of ingestion 175 (58.9) 166 (57.4)
Lavage 208 (70.0) 154 (53.3)***
Lavage—primary hospital only 46 (15.5) 39 (13.5)
Lavage—study hospital only 123 (41.4) 87 (30.1)
Lavage—both 39 (13.1) 28 (9.7)
Adsorbent 254 (85.5) 241 (83.4)
Adsorbent–Fullers Earth only 237 (79.8) 220 (76.1)
Adsorbent—activated charcoal only 13 ( 4.4) 6 ( 2.1)
Adsorbent–both 4 (1.3) 15 ( 5.2)
Intravenous fluids 283 (95.3) 262 (90.7)*
Diuretics 26 ( 8.8) 33 (11.4)
Antiemetic 38 ( 12.8) 51 ( 17.6)
Magnesium 2 ( 0.7) 6 ( 2.1)
Prednisolone 50 (16.8) 28 ( 9.7)*
Cyclophosphamide 34 (11.4) 39 (13.5)
*p , 0.05.
**p , 0.01.
***p , 0.001.
doi:10.1371/journal.pmed.0050049.t004
Table 5. Vital Status of Patients at Three Months Following Paraquat Ingestion in the Formulation Groups
Outcome 3 Mo
after Ingestion
Standard Formulation
Cases before 1/10/04
Confirmed, Probable, or
Possible INTEON Cases
(after Washout Period)
Dead (%) 215 (72.4%) 182 (63.0%)
Alive (%) 76 (25.6%) 103 (35.6%)
Lost to follow-up (%) 6 (2.0%) 4 (1.4%)
Total 297 289
doi:10.1371/journal.pmed.0050049.t005
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units reported no change in the number of patients seen
since the introduction of INTEON, whereas 29% reported a
decrease and 8% an increase. Virtually all hospitals that were
able to provide information had not changed their referral
pattern of paraquat-poisoned patients, and there was no
difference between the larger and smaller units.
Discussion
In Sri Lanka, pesticides are the most common means of self
poisoning, with case fatality ratios more than 10-fold higher
than those from self-poisoning in industrialised countries
[15]. Although not the most common cause of pesticide death,
paraquat has a higher case fatality ratio than other commonly
ingested pesticides [16]. We have shown in this study that the
development of a new formulation that turns to a gel in the
stomach, slowing absorption and increasing the time avail-
able for effective emesis, increases estimated 3-mo survival
from 27.1% for patients ingesting the standard formulation
to 36.7% with the INTEON product. In individual terms this
equates to approximately 30 lives saved within the survey due
to the introduction of INTEON.
Despite much research into the mechanism of toxicity and
the potential for treatment of paraquat poisoning, no speciﬁc
therapy has so far been shown to affect outcome in controlled
clinical studies [5,6,17]. Consequently, prevention of absorp-
tion remains an important approach to reduce paraquat
toxicity. For this reason a potent emetic has been included in
paraquat formulations since the late 1970s [9]. However, a
beneﬁcial effect of this measure on case fatality has not been
conclusively demonstrated [11,18–22]. This may be related to
the relatively large quantities of product that are often
ingested in self-harm cases.
Paraquat causes mucosal damage and increases passive ﬂux
across the mucosal barrier at high concentrations [23], and
peak plasma levels occur within one hour, since the liquid
formulation rapidly reaches the absorptive site in the small
intestine [6]. The principle of the INTEON formulation is
based on the addition of alginates, which become protonated
after contact with gastric acid and transformed into a
gelatinous mixture. This technology is used in pharmaceut-
icals to treat heartburn and acid reﬂux [24] and to cause
satiety in the treatment of obesity, by virtue of the intra-
gastric bulking of alginates [25]. In vitro and in vivo studies
have shown that the inclusion of the alginate into the
formulation led to a decrease in paraquat absorption [12].
The combination of the alginate with an increased emetic
concentration and magnesium sulphate added as purgative is
considered to be necessary to achieve an optimum safening
effect. The INTEON formulation introduced into Sri Lanka
also contained a built-in surfactant system. Some of the
Figure 1. Kaplan-Meier Survival Curves for Patients Ingesting Standard
and INTEON Formulation
doi:10.1371/journal.pmed.0050049.g001
Figure 2. Kaplan-Meier Survival Curves by Formulation Group and Ingestion Amount
doi:10.1371/journal.pmed.0050049.g002
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in the bottle with prolonged storage, creating a surfactant
and emetic-rich phase, and one with increased paraquat and
alginate concentration. Although the formulation could be
easily rehomogenised by light agitation of the bottle the
overall safening effect may potentially have been suboptimal.
Although steps were taken to actively withdraw the old
product from the market when the new formulation was
introduced, we recognised that there would be a period in
which the old product would still be with farmers. It was
therefore important to unequivocally identify as many cases
as possible through analysis of the marker that had been
added to the INTEON product in a plasma or urine sample.
However, this identiﬁcation was possible only in two-thirds of
the INTEON cases due to a combination of samples not being
taken (e.g., in patients who were very ill on admission and
died quickly) and samples with plasma paraquat concen-
trations so low that the diquat marker could not be detected.
To reduce the number of standard formulation cases
incorrectly included in the INTEON group we introduced
washout periods for the centres. During the washout periods
only 6/44 (14%) of patients with sample conﬁrmation were
INTEON ingestions. In contrast, 195/242 (81%) of patients
with samples after the washout period had ingested INTEON.
Hence, it is likely that the majority of the 89 possible
INTEON cases after the washout period were correctly
classiﬁed as INTEON cases. Only 18 cases with no sample
information or equivocal results occurred during the washout
period and had to be excluded from the survival analyses.
Importantly, the sensitivity analyses excluding those patients
without sample or bottle conﬁrmation gave very similar
results to the primary analysis, providing further evidence
that our overall classiﬁcation of cases was largely correct. The
possible inclusion of a small number of standard formulation
cases in the INTEON group may have had a small impact on
the survival rate. However, the effect of not including
possible INTEON formulation cases would have been far
greater because of (a) missing cases with large ingestion
volumes because of the difﬁculty of collecting samples from
very sick patients, and (b) missing ingestions too small for the
marker to be detectable in samples.
Ingestion information was not available for 26% of
standard formulation cases and 14% of INTEON ingestions.
The higher proportion of standard formulation cases with
missing ingestion information resulted because information
was not routinely collected at the start of the survey at one
hospital. Many of the other patients without an ingestion
amount were too ill to supply this information. Standard
formulation patients with ingestion information tended to
have ingested more than INTEON patients, and 29% had
ingested more than 100 ml compared with 17% of INTEON
patients. However, this difference in ingestion amounts
would only explain a small part of the observed improvement
in survival since standardising the survival rate of the
standard formulation cases with ingestion information to
the ingestion amount distribution of the INTEON patients
only increased the estimated survival probability of standard
formulation cases from 27.1% to 27.7%. Furthermore,
standard formulation cases without ingestion information
appeared to have ingested less than INTEON patients without
ingestion information based on their higher survival rate, and
the ingestion distributions of the full groups were probably
closer than those of the subgroups with ingestion informa-
tion.
Since the INTEON formulation was introduced in the
whole country at the same time we had to rely on a before-
and-after design for the survey. It is therefore possible that
changes in treatment, hospital admissions, or referrals may
have occurred over the period of the survey. There were some
differences between the two groups in terms of treatment,
with fewer INTEON patients receiving gastric lavage and
prednisolone, but none of the differences were major
confounders of the observed beneﬁcial effect of INTEON
on survival. Table 6 shows that the hazard ratios with and
without covariate adjustment are very similar, suggesting that
the differences in treatment explain very little of the group
difference in survival. There is a difference in crude survival
rate between those who had lavage and those who did not, but
the effect disappears when adjustment is made for ingestion
amount. The lower rate of lavage in the INTEON group is
more likely a consequence of factors such as the higher rate
of early emesis and not an explanation for improved survival.
There were a number of patients who stated that they had
ingested very small amounts of either formulation but had a
rapid onset of emesis. It is suspected that some of these
patients ingested much more than stated and hence that
rapid onset of emesis in the lower exposure groups may be an
indicator of misreported exposure.
Table 6. Hazard Ratios for INTEON Formulation from Cox Proportional Hazards Regression Models
Participants
Included
in Analysis
No Stratification;
no Covariate
Adjustment
Stratification for
Centre; No
Covariate
Adjustment
Stratification for Centre;
Adjustment for All
Covariates Except
Ingestion Amount
Stratification for Centre;
Adjustment for All
Covariates Including
Ingestion Amount
(Continuous Variable)
Hazard Ratio
(95% CI)
p-Value Hazard Ratio
(95% CI)
p-Value Hazard Ratio
(95% CI)
p-Value Hazard Ratio
(95% CI)
p-Value
All participants
a 0.73 (0.60–0.89) 0.002 0.77 (0.62–0.95) 0.014 0.71 (0.57–0.87) 0.001 — —
Participants with
ingestion information
b
0.63 (0.50–0.78) ,0.001 0.66 (0.52–0.85) 0.001 0.61 (0.47–0.78) ,0.001 0.67 (0.52–0.87) 0.002
aStandard formulation: n ¼ 297; INTEON: n ¼ 289
bStandard formulation: n ¼ 221; INTEON: n ¼ 248
doi:10.1371/journal.pmed.0050049.t006
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Survival after Paraquat IngestionThe monthly admissions over the study period suggest an
overall decrease of the number of cases over time. In the
survey of peripheral hospitals and care units there was no
indication of a change in their referral practices over time.
Changes in case ascertainment and management are there-
fore unlikely to have substantially contributed to the
improved survival noted with INTEON. However, many
hospitals indicated that the number of paraquat cases had
decreased. This change may relate to shifts in the general
pattern of self-harm incidents, but it is also possible that
fewer patients ingesting the INTEON formulation were
seeking health care.
For those patients who did not survive, there was an
increase in time to death for INTEON compared to the
standard formulation. This difference may become important
when trying to achieve improvements in the treatment of
paraquat poisoning, as it may allow more time for new or
existing therapies to become effective. Our data show that in
Sri Lanka self-harm patients reach hospital reasonably
quickly (nearly 60% are treated within 4 h), so improved
treatment of poisoning cases in addition to the INTEON
formulation could have a further positive effect on survival.
While our ﬁnding of improved survival of patients in the
INTEON group is encouraging the data also show that the
beneﬁcial effect of the formulation is limited by the amount
of product ingested, since this was the single most important
predictor of survival in both groups. It is therefore apparent
that formulation changes in themselves will not be sufﬁcient
to comprehensively address the problem of mortality from
self-harm with paraquat. An integrated approach has recently
been proposed including generic measures to reduce self-
harm incidents, as well as focusing on reducing access,
reducing formulation toxicity (e.g., by reducing formulation
strength), and improving the treatment of poisoning [26].
However, there are clear tensions between what is desirable
from public health, agricultural, and industry perspectives,
and this lies at the heart of the controversy over the beneﬁts
and risks of paraquat use, in particular in developing
countries. A detailed discussion of this subject is beyond the
scope of this paper, but can be found elsewhere [27–29].
Nevertheless, it is evident that, as long as paraquat and other
potentially harmful pesticides continue to be widely used, a
comprehensive programme to prevention and management
of poisoning is needed. This is why the World Health
Organization (WHO) has announced a public health initiative
with the overall goal to reduce morbidity and mortality from
pesticide poisoning, including improved regulatory policies,
epidemiological surveillance, improved medical management
and mental health-care, training in the safe handling of
pesticides, and community programmes that minimise the
risk of intentional and unintentional poisonings [1].
In conclusion, this survey shows that the introduction of a
new paraquat formulation with INTEON technology has led
to a signiﬁcant improvement in survival of patients with
paraquat poisoning. Our statistical analyses indicate that this
effect is due to a real difference between the two formula-
tions. Patients who ingested a lethal amount of the
formulation survived longer with INTEON, raising the
prospect of more opportunities for treatment. These encour-
aging results were achieved despite suboptimal homogeneity
of the formulation, and future improvements in formulation
technology may reduce overall toxicity even further.
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Survival after Paraquat IngestionEditors’ Summary
Background. Paraquat is a non-selective herbicide used in many
countries on a variety of crops including potatoes, rice, maize, tea,
cotton, and bananas. It is fast-acting, rainfast, and facilitates ‘‘no-till’’
farming, but it has attracted controversy because of the potential for
misuse, particularly in developing countries. Better training of workers
has been shown to reduce the number of accidents, and additions to the
liquid formulation have contributed to a reduction in cases where
paraquat was drunk by mistake—blue color and a stench agent made it
less attractive to drink, and an emetic to induce vomiting aimed to
reduce the time it is retained in the body.
Why Was This Study Done? Despite the changes made to the
formulation, paraquat is still taken deliberately as a poison by agricultural
workers in parts of the developing world. Although other pesticides
cause more deaths overall, paraquat poisoning is more frequently fatal
than other common pesticides. Syngenta, a commercial producer of
paraquat, has developed a new paraquat formulation designed to
reduce its toxicity. Syngenta introduced the new formulation in Sri
Lanka, a country well known for its high level of suicides with pesticides,
in 2004. This new formulation includes three components designed to
reduce paraquat absorption from the stomach and intestines: a gelling
agent to thicken the formulation in the acidic environment of the
stomach and slow its passage into the small intestine; an increase in the
amount of emetic to induce more vomiting more quickly; and a
purgative to speed its exit from the small intestine, the main site of its
absorption. The researchers wished to know whether the new
formulation could contribute to improved survival in instances where
paraquat had been ingested.
What Did the Researchers Do and Find? The researchers gathered
information on the time and circumstances of when paraquat was taken,
the amount that was taken, the times, and details of any vomiting,
treatment, and outcomes for cases of attempted suicide by paraquat
poisoning at nine large hospitals in agricultural regions of Sri Lanka from
December 2003 to January 2006. In total, 774 patients were tracked in
this time. Syngenta introduced the new formulation in Sri Lanka on 1
October 2004. The researchers gathered information on the formulation
involved in subsequent cases, by either interview or analysis of samples.
After excluding some unusual or less certain cases, they analyzed data on
586 patients, of whom 297 had deliberately taken the standard
formulation and 289 the new formulation.
Although the new formulation was still toxic, the data showed an
increase in the proportion of cases surviving for at least three months—
from 27% (standard formulation) to 37% (new formulation), an effect
that was unlikely to be due to chance. More patients vomited within 15
minutes of taking the new formulation of paraquat. Patients who died
generally survived longer if they had taken the new rather than the
standard formulation. The researchers estimated that the new formula-
tion is just over half as toxic as the standard formulation, meaning that a
patient was likely to suffer the same level of ill effects after taking twice
as much of the new formulation compared to the standard formulation.
What Do these Findings Mean? This study was designed, funded, and
led by Syngenta, the manufacturer of the standard and new formulations
of paraquat but the study team included a number of independent Sri
Lankan and international scientists. As the researchers observed the
effects of the introduction of the new formulation across the entire
country at the same time, they could not completely rule out other
possible reasons for the differences in outcomes for those who had
taken the two formulations, such as differences in treatment.
Despite this inherent drawback, the researchers estimate that during the
study the new formulation saved about 30 lives. They conclude that the
the new formulation does reduce the amount of paraquat absorbed by
the body, although the study does not answer the question whether this
was due to the gelling agent, the increased emetic in the new
formulation or a combination of factors. The researchers suggest that
the new formulation, by keeping patients alive longer, may allow doctors
more time to treat patients. As no effective treatment exists at present,
this benefit relies on a treatment being developed in the future.
The researchers note that the most important factor in predicting the
outcome when paraquat has been taken deliberately is the dose. As a
result, they suggest that the new formulation can only be one part of a
wider strategy to reduce deaths by deliberate self-poisoning using
paraquat. They suggest that such an integrated approach might include
generic measures to reduce incidents of self-harm, reduced access to
paraquat, reduced formulation strength, and improvements in treat-
ment.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050049.
  The US Environmental Protection Agency has published its Reregistra-
tion Eligibility Decision for paraquat
  The Department of Health and Human Services of the US Centers for
Disease Control and Prevention provides a fact sheet on how to
handle paraquat and suspected cases of exposure
  The World Health Organisation has recently finished consulting on a
draft Poisons Information Monograph for paraquat
  The International Programme on Chemical Safety (IPCS) has published
a review of paraquat in its Environmental Health Criteria Series
  MedlinePlus provides links to information on health effects of
paraquat
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